|Poll|July 23, 2012

Laryngeal Mass Discovered in 46-Year-Old Man

A 46-year-old man presented with a history of dyspnea and pain of several days duration. The patient does not disclose any pertinent history and has been well otherwise. Radiographic evaluation revealed the presence of a laryngeal mass. Surgical resection was performed.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Laryngeal Mass Discovered in 46-Year-Old Man

Related Content

38-Year-Old Woman With Breast Mass

52-Year-Old Woman With Dysphagia and Dyspnea and Nodule in Neck

56-Year-Old Man With Subcutaneous Soft Tissue Mass in Right Leg

Thyroid Nodule Found in 43-Year-Old Man

23-Year-Old Woman Presents With Cervical Lymphadenopathy

Latest CME

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Arkansas Association of Cancer Professionals

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Minnesota

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – West Virginia

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – North Carolina

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Nevada Oncology Society

Kansas Society of Clinical Oncology

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Rhode Island Oncology Society

Satellite Symposia at the Annual Radiation Oncology Meeting

27th Annual International Lung Cancer Congress®

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

North Carolina Oncology Association

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Montana/Wyoming

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Tennessee Oncology Practice Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Nevada Oncology Society

Washington State Medical Oncology Society

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Missouri Oncology Society

New Mexico Society of Clinical Oncology

Louisiana Oncology Society

Nevada Oncology Society

Show Me the Data: Immunotherapy Across the Hepatobiliary Cancer Continuum—From Embolization-Eligible HCC to Advanced Biliary Tract Cancers

Wyoming State Oncology Society

Montana State Oncology Society

Wisconsin Association of Hematology and Oncology

Kentucky Society of Clinical Oncology

44th Annual CFS®: Innovative Cancer Therapy for Tomorrow™

Rhode Island Oncology Society

9th Annual School of Nursing Oncology™

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Optimizing Multidisciplinary Care in TGCT

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

Trending on CancerNetwork

FDA Approves Lutetium Lu 177 Dotatate Injection for GEP-NETs

SOHO 2026 Sessions Reveal Key Updates Across Leukemia Populations

FDA Approves Topical Gel for Superficial Basal Cell Carcinoma

Camizestrant Combo Misses PFS End Point in First-Line ER+/HER2– Breast Cancer

FDA Extends Review of Zanzalintinib Combo in Pretreated Metastatic CRC